For managing the symptoms of the disease, a cholinesterase inhibitor (donepezil, galantamine, and rivastigmine) is prescribed in mild and moderate AD and memantine is recommended in moderate AD cases who cannot use cholinesterase inhibitors and also in severe AD.10 The annual cost of care services for a patient with AD in severe stage is about 50000 US dollars (USD).2 The global cost of dementia increased from 604 billion USD in 2010 to 818 billion USD in 2015 and about half of this amount belongs to AD. This evidence concerns the gene BCHE and Alzheimer disease.